bah-roo

StockMarketInsights

  • Cramer’s Right on Marvell — and Way Too Casual on Bausch’s Risk

    Cramer’s Right on Marvell — and Way Too Casual on Bausch’s Risk

    When Jim Cramer says “buy,” Wall Street listens. Retail traders sprint. And somewhere, a hedge fund quietly takes the other side. Now he’s bullish on Marvell (MRVL) and Bausch Health (BHC). Two very different beasts — one riding the AI semiconductor wave, the other dragging around a pharmaceutical debt hangover. So the question isn’t whether…

  • Hims Isn’t a Hype Trade — It’s a Margin Fight in Disguise

    Hims Isn’t a Hype Trade — It’s a Margin Fight in Disguise

    Hims stock keeps forcing the same question: is this a real consumer-health compounder, or just a very well-marketed trade riding the GLP‑1 wave? The answer is uncomfortable for both bulls and bears. HIMS is a real business with real operating leverage. It’s also flirting with a growth model that keeps running headfirst into margin gravity…

  • Hims Bet Big on GLP‑1s—and Tripped Over the Bill

    Hims Bet Big on GLP‑1s—and Tripped Over the Bill

    Is Hims a breakout growth trade or a crowded telehealth short? After the latest earnings and its GLP‑1 faceplant, it’s both — just not in the way the bulls want. Here’s the blunt take: Hims didn’t pivot to GLP‑1s. It lunged. And now the bill’s due. Start with the bull case, because it’s real. Hims…

  • AI Stocks Aren’t Overpriced — Expectations Are

    AI Stocks Aren’t Overpriced — Expectations Are

    AI stocks aren’t expensive because the future is bright. They’re expensive because investors are confusing inevitability with inevitability of profits. And that mistake is quietly warping how the market prices the real infrastructure winners: NVIDIA, hyperscale cloud providers, and the data platforms everyone claims to need. Here’s the uncomfortable truth. AI is real. The spending…